Clinical Trial Update: Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating FOLFIRINOX with or without SBRT in locally advanced pancreatic cancer has completed and results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• FOLFIRINOX (mFFX) (modified FOLFIRINOX)
• SBRT (stereotactic body radiotherapy)

Snippet

Sponsor: Stanford University | Conditions: Pancreatic Cancer | Phase 3 | Status: COMPLETED | Results posted: 2022-10-28